Dechra Pharmaceuticals PLC (LSE:DPH) - Share price


Stock Report

Dechra Pharmaceuticals PLC DPH

Last Price
GBX2,722.00

Day Change
10.00|0.37%

As of 19/11/2019
09:00:55 GMT | GBX
Minimum 15 Minutes Delay.

Last Close2,712.00p
Day Range2,714.00 - 2,736.00
Mkt Cap2.79Bil
52-Wk Range1,992.00 - 3,080.00
Yield %1.16
ISINGB0009633180
Volume8,653
P/E90.09
P/S0.06
P/CF0.34

Share Price

Total Returns 18/11/2019

 Chg (%)  
More ...
Dechra Pharmaceuticals PLC4.12 
FTSE 100 TR GBP2.54
 
Financials
201720182019
More ...
Income Statement
Turnover359.30407.10481.80
Operating Profit36.7040.0045.50
Net Profit26.1036.1030.90
Reported EPS27.9337.0430.07
Balance Sheet
Current Assets185.00247.90292.10
Non Current Assets453.10769.40756.40
Total Assets638.101,017.301,048.50
Current Liabilities66.4091.60118.10
Total Liabilities---
Total Equity302.60505.00509.10
Cash Flow
Operating Cash Flow89.4075.5099.10
Net Change in Cash21.8016.10-0.20

Regulatory News

DateAuthor Headline
20/07/2018David Brenchley 5 Best Investment Trusts of 2018
Two Baillie Gifford closed-end funds are the best performing trusts of 2018, while emerging market funds continued to struggle
26/03/2018David Brenchley 3 Top Rated Trusts Trading on Double Digit Discounts
Closed-end funds invested in UK stocks are suffering from falling investor confidence as Brexit negotiations rumble on, potentially creating investment opportunities
23/11/2017David Brenchley Top Smaller Company Stocks for Growth Investors
Smaller companies were the winners from yesterday's Budget. Here are two AIM-listed firms and three top-rated funds to play the small-cap space
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
20/09/2019Sale of OptionMr. Ian David Page2,789.3834,536963,338.00
20/09/2019Sale of OptionMr. Anthony Griffin2,789.3820,858581,808.00
19/09/2019Exercise of OptionMr. Ian David Page0.0073,2600.00
19/09/2019Exercise of OptionMr. Anthony Griffin0.0020,8580.00

Company Profile

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The company is engaged in development, manufacture and marketing of products for veterinarians.

Sector

Drug Manufacturers - General

Index

FTSE 250 ,FTSE 350 ,FTSE All Share

Next Event 24/02/2020

Half-Yearly Results
Ratios
Comp
More ...
PER (E)87.46
Div Yld (E)1.20
PEG (E)0.00
ROCE4.12
Op Mrgn0.09
EPS Grwth-0.11
Dividends
PreviousLatest
More ...
Record Date08/03/1925/10/19
Ex-Div07/03/1924/10/19
Paid08/04/1915/11/19
Amnt9.5022.10
Directors
More ...
Non-Executive DirectorJulian Heslop
Executive Director, Chief ExecutiveMr. Ian David Page
Non-Executive Director, ChairmanMr. William Anthony Rice
Non-Executive DirectorMs. Ishbel Jean Stewart Macpherson
Executive Director, Chief Financial OfficerPaul Sandland
Executive DirectorMr. Anthony Griffin
Non-Executive DirectorDr. Lawson Macartney
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2019 Morningstar. All rights reserved.